Philosys Healthcare Rises 29.81% Amid Uptrend in COVID-19 (Diagnosis/Treatment/Vaccine Development) Theme

On the 18th, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.09% compared to the previous day, showing strength, while Philosis Healthcare, a related stock attracting attention, surged by 29.81% compared to the previous day. Philosis Healthcare is known as a specialized manufacturer of digital set-top boxes.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to provisional data compiled at 11:06, foreigners are net selling -12,000 shares of Philosis Healthcare.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)



According to the analysis by Thinkpool Robo Algorithm RASSI, Philosis Healthcare’s quant financial score is 1.16 points, which is lower in stability, profitability, and growth compared to the average of other stocks related to COVID-19 (diagnosis/treatment/vaccine development, etc.). This can be interpreted as Philosis Healthcare having relatively low investment attractiveness compared to other stocks from a financial perspective. On the other hand, United Pharm ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top financial scores within the theme


※ The quant financial score is the result of analysis by the robo algorithm based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real time by an article automatic generation algorithm jointly developed by Asia Economy and financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.